Literature DB >> 18519718

Relationship between various definitions of prior antibiotic exposure and piperacillin-tazobactam resistance among patients with respiratory tract infections caused by Pseudomonas aeruginosa.

Nimish Patel1, Louise-Anne McNutt, Thomas P Lodise.   

Abstract

Contemporary literature lacks a definition of prior antibiotic exposure which captures all patients at risk of developing piperacillin-tazobactam-resistant Pseudomonas aeruginosa (PTR-PA). The results indicated that individual antibiotics that are associated with PTR-PA differ depending on the definition of prior antibiotic exposure utilized. When the specific antibiotic used was replaced by the number of prior exposures, the number of exposures was the only variable associated with an increased risk of antibiotic resistance at each time threshold.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18519718      PMCID: PMC2493121          DOI: 10.1128/AAC.00456-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Estimating the relative risk in cohort studies and clinical trials of common outcomes.

Authors:  Louise-Anne McNutt; Chuntao Wu; Xiaonan Xue; Jean Paul Hafner
Journal:  Am J Epidemiol       Date:  2003-05-15       Impact factor: 4.897

2.  Easy SAS calculations for risk or prevalence ratios and differences.

Authors:  Donna Spiegelman; Ellen Hertzmark
Journal:  Am J Epidemiol       Date:  2005-06-29       Impact factor: 4.897

3.  Experiments to determine whether recursive partitioning (CART) or an artificial neural network overcomes theoretical limitations of Cox proportional hazards regression.

Authors:  M W Kattan; K R Hess; J R Beck
Journal:  Comput Biomed Res       Date:  1998-10

4.  Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes.

Authors:  Donald I Hsu; Mark P Okamoto; Rekha Murthy; Annie Wong-Beringer
Journal:  J Antimicrob Chemother       Date:  2005-02-22       Impact factor: 5.790

5.  Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa.

Authors:  Cheol-In Kang; Sung-Han Kim; Wan Beom Park; Ki-Deok Lee; Hong-Bin Kim; Eui-Chong Kim; Myoung-Don Oh; Kang-Won Choe
Journal:  Microb Drug Resist       Date:  2005       Impact factor: 3.431

6.  An introduction to multivariate adaptive regression splines.

Authors:  J H Friedman; C B Roosen
Journal:  Stat Methods Med Res       Date:  1995-09       Impact factor: 3.021

7.  Use of different thresholds of prior antimicrobial use in defining exposure: impact on the association between antimicrobial use and antimicrobial resistance.

Authors:  Emily P Hyle; Leanne B Gasink; Darren R Linkin; Warren B Bilker; Ebbing Lautenbach
Journal:  J Infect       Date:  2007-09-12       Impact factor: 6.072

8.  Risk factors associated with ampicillin-resistant infection in newborns in the era of group B streptococcal prophylaxis.

Authors:  Alison C Rentz; Matthew H Samore; Gregory J Stoddard; Roger G Faix; Carrie L Byington
Journal:  Arch Pediatr Adolesc Med       Date:  2004-06

9.  Identification of patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk of infection with carbapenem-resistant isolates.

Authors:  Thomas P Lodise; Chris Miller; Nimish Patel; Jeffrey Graves; Louise-Anne McNutt
Journal:  Infect Control Hosp Epidemiol       Date:  2007-06-22       Impact factor: 3.254

10.  Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity.

Authors:  Elisabeth Paramythiotou; Jean-Christophe Lucet; Jean-François Timsit; Dominique Vanjak; Catherine Paugam-Burtz; Jean-Louis Trouillet; Stéphanie Belloc; Najiby Kassis; Andreas Karabinis; Antoine Andremont
Journal:  Clin Infect Dis       Date:  2004-02-17       Impact factor: 9.079

View more
  6 in total

1.  The quick loss of carbapenem susceptibility in Pseudomonas aeruginosa at intensive care units.

Authors:  Yamin Zou; Jiangping Lian; Ying Di; Haisheng You; Hongping Yao; Junhui Liu; Yalin Dong
Journal:  Int J Clin Pharm       Date:  2017-11-14

2.  Evaluating the appropriateness of carbapenem and piperacillin-tazobactam prescribing in a tertiary care hospital in Saudi Arabia.

Authors:  Nada A Alsaleh; Hussain A Al-Omar; Ahmed Y Mayet; Alexander B Mullen
Journal:  Saudi Pharm J       Date:  2020-09-25       Impact factor: 4.330

3.  Acquisition of Pseudomonas aeruginosa and its resistance phenotypes in critically ill medical patients: role of colonization pressure and antibiotic exposure.

Authors:  Nazaret Cobos-Trigueros; Mar Solé; Pedro Castro; Jorge Luis Torres; Cristina Hernández; Mariano Rinaudo; Sara Fernández; Álex Soriano; José María Nicolás; Josep Mensa; Jordi Vila; José Antonio Martínez
Journal:  Crit Care       Date:  2015-05-04       Impact factor: 9.097

4.  Risk factors and the resistance mechanisms involved in Pseudomonas aeruginosa mutation in critically ill patients.

Authors:  Stéphanie Druge; Stéphanie Ruiz; Fanny Vardon-Bounes; Marion Grare; François Labaste; Thierry Seguin; Olivier Fourcade; Vincent Minville; Jean-Marie Conil; Bernard Georges
Journal:  J Intensive Care       Date:  2019-07-19

5.  Modeling the impact of interventions against Acinetobacter baumannii transmission in intensive care units.

Authors:  Tan N Doan; David C M Kong; Caroline Marshall; Carl M J Kirkpatrick; Emma S McBryde
Journal:  Virulence       Date:  2015-08-07       Impact factor: 5.882

6.  Evaluation of Risk Factors for Antibiotic Resistance in Patients with Nosocomial Infections Caused by Pseudomonas aeruginosa.

Authors:  Meliha Cagla Sonmezer; Gunay Ertem; Fatma Sebnem Erdinc; Esra Kaya Kilic; Necla Tulek; Ali Adiloglu; Cigdem Hatipoglu
Journal:  Can J Infect Dis Med Microbiol       Date:  2016-08-30       Impact factor: 2.471

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.